Early-stage Hodgkin's lymphoma: In pursuit of perfection

Journal of Clinical Oncology

Volumn 30, Issue 9, 2012, Pages 895-896

  Younes, Anas ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; DRUG DOSE ESCALATION; DRUG EFFICACY; EARLY CANCER; EDITORIAL; FEMALE FERTILITY; FEMALE INFERTILITY; HODGKIN DISEASE; HUMAN; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SIDE EFFECT; CHEMORADIOTHERAPY; FEMALE; MALE; NOTE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY; FEMALE; HODGKIN DISEASE; HUMANS; MALE;

EID: 84860601872     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.40.1661     Document Type: Editorial

References (11)

1. Siegel R, Ward E, Brawley O, et al: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61:212-236, 2011
2. Armitage JO: Early-stage Hodgkin's lymphoma. N Engl J Med 363:653-662, 2010
3. Gordon LI, Hong F, Fisher RI, et al: A randomized phase III trial of ABVD vs. Stanford V +/- radiation therapy in locally extensive and advanced stage Hodgkin's lymphoma: An intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496). 52nd ASH Annual Meeting & Exposition, Orlando, FL, December 4-7, 2010 (abstr 415)
4. Advani R, Hong F, Fisher RI, et al: Randomized phase III trial comparing ABVD +radiotherapy and the Stanford V regimen in patients with stage I/II bulky mediastinal Hodgkin lymphoma: A subset analysis of the US Intergroup Trial E2496. 52nd ASH Annual Meeting & Exposition, Orlando, FL, December 4-7, 2010 (abstr 416)
5. Engert A, Plütschow A, Eich HT, et al: Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 363:640-652, 2010
6. von Tresckow B, Plütschow A, Fuchs M, et al: Dose-intensification in early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin Study Group HD14 trial. J Clin Oncol 30:907-913, 2012
7. Hutchings M, Barrington SF: PET/CT for therapy response assessment in lymphoma. J Nucl Med 50:21S-30S, 2009
8. Gallamini A, Hutchings M, Rigacci L, et al: Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study. J Clin Oncol 25:3746-3752, 2007 (Pubitemid 47372616)
9. Buglio D, Georgakis GV, Hanabuchi S, et al: Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 112:1424-1433, 2008
10. Weihrauch MR, Manzke O, Beyer M, et al: Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: Potential for a prognostic factor. Cancer Res 65:5516-5519, 2005 (Pubitemid 40911150)
11. van den Berg A, Visser L, Poppema S: High expression of the CC chemokine TARC in Reed-Sternberg cells: A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol 154:1685-1691, 1999 (Pubitemid 29262850)